Latest state-of-the-art health check-up technology comes to Thailand

Press Releases »

          Verita Health MahaNakhon (VMH) is introducing "Verita Wisdom", a new 360° state-of-the-art Cardiometabolic Health Check to Thailand to analyze customers' cardiovascular risk situation within 30 minutes.
          "We are delighted to be able to exclusively offer this latest state-of-the-art medical technology from Germany to our customers in Thailand. To launch this advanced medical check-up technology, we are offering a special package of THB 8,500 from now until December 31, 2018", revealed Julius Andriesz, CEO of Verita Healthcare Group. The normal price of this check-up package costs THB 12,500.
          Clients taking advantage of the "Verita Wisdom" Cardiometabolic Health Check will be able to receive a detailed overview of their health with deep insights in cardiovascular condition within 30 minutes along with identifying possible problematic areas as well as prioritized recommendations to improve their wellbeing in the long term.
          For appointments or further details, please contact Verita Health MahaNakhon Tel. 0-2115-7553 or E-mail: [email protected].

Latest state-of-the-art health check-up technology comes to Thailand

ข่าวcardiovascular risk+o:genวันนี้

Unithai Group restores Mangrove Ecosystem on Earth Day to expand green areas and conserve the Environment

Unithai Group restores Mangrove Ecosystem on Earth Day to expand green areas and conserve the Environment, in line with Sustainable Business Practices and Community, Social, and Environmental Stewardship Unithai Group, led by Unithai Container Terminal and its subsidiaries, organized "Mangrove Planting, Reviving the Sea" on April 25, 2025, at Bang Pu Recreation Center. This initiative was part of an environmental campaign to commemorate Earth Day and reaffirm the Group's commitment to

ไทยพีบีเอส เดินหน้าสร้างสรรค์เนื้อหาคุณภา... ไทยพีบีเอส เปิดตัวละครชุด "ทุนไทย" 6 เรื่อง 12 ตอน "ร้อยทุนวัฒนธรรมรสไทยไว้ในละคร" — ไทยพีบีเอส เดินหน้าสร้างสรรค์เนื้อหาคุณภาพ เปิดตัว "ทุนไทย" ละครชุดพิ...

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major...

Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Ozempic(R) (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack,...

Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1...

Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer

A Working Group of representatives from seven international health-care organizations call for improved blood pressure (BP) goal rate levels of patients...

New Data Show Xenical(R) Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People

The weight loss medication Xenical(R) (orlistat 120mg) significantly reduces weight and improves cardiovascular risk factors such as blood pressure, glycaemic...

DATA DEMONSTRATE IMPACT OF WEIGHT LOSS WITH SIBUTRAMINE ON CARDIOVASCULAR RISK FACTORS FOR OBESE PATIENTS

Bangkok--Jun 4--Weber Shandwick (Thailand) Data Address Positive Impact of Weight Loss with Sibutramine On Cardiovascular Risk Factors of Metabolic Syndrome, Left Ventricular Mass, and Predicted...